CN Patent

CN110913843B — 药物组合物

Assigned to Eli Lilly and Co · Expires 2022-09-13 · 4y expired

What this patent protects

本发明涉及二甲双胍、阿托伐他汀和缬沙坦或其药学上可接受的盐的固体口服固定剂量组合物、其制备方法和该组合物在治疗某些疾病中的用途。

USPTO Abstract

本发明涉及二甲双胍、阿托伐他汀和缬沙坦或其药学上可接受的盐的固体口服固定剂量组合物、其制备方法和该组合物在治疗某些疾病中的用途。

Drugs covered by this patent

Patent Metadata

Patent number
CN110913843B
Jurisdiction
CN
Classification
—
Expires
2022-09-13
Drug substance claim
No
Drug product claim
No
Assignee
Eli Lilly and Co
Source
FDA Orange Book + USPTO grounding via Google Patents

Bibliographic data sourced from FDA Orange Book + USPTO public records. Plain-English summary generated by AI grounded in source text. Patent term extensions (PTR, SPC, pediatric) may shift the effective expiry. Not legal advice.

Track this patent

Get a daily-checked alert when vulnerability score, expiry, classification, or assignee changes. Email, Slack, or Teams delivery. Pro: 50 watches, Free: 3.